72 related articles for article (PubMed ID: 12454367)
1. Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study.
Meenakshi A; Kumar RS; Siva Kumar N; Ganesh V
Hum Antibodies; 2002; 11(3):73-7. PubMed ID: 12454367
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185.
Meenakshi A; Kumar RS; Ganesh V; Sivakumar N
Hum Antibodies; 2003; 12(4):123-7. PubMed ID: 15156100
[TBL] [Abstract][Full Text] [Related]
3. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
Meenakshi A; Kumar RS; Kumar NS
Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
[TBL] [Abstract][Full Text] [Related]
4. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
5. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
6. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
8. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer.
Troncone G; Panico L; Vetrani A; de Divitiis B; Zeppa P; Fulciniti F; Pettinato G; Palombini L
Diagn Cytopathol; 1996 Mar; 14(2):135-9. PubMed ID: 8964169
[TBL] [Abstract][Full Text] [Related]
9. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
Pupa SM; Ménard S; Andreola S; Colnaghi MI
Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
11. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas.
Suo Z; Su W; Holm R; Nesland JM
Anticancer Res; 1995; 15(6B):2797-8. PubMed ID: 8669867
[TBL] [Abstract][Full Text] [Related]
12. C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2.
Taylor SL; Rudland PS; Barraclough R
Oncol Res; 1999; 11(7):311-7. PubMed ID: 10757445
[TBL] [Abstract][Full Text] [Related]
13. Absence of HER2 overexpression in metastatic malignant melanoma.
Inman JL; Kute T; White W; Pettenati M; Levine EA
J Surg Oncol; 2003 Oct; 84(2):82-8. PubMed ID: 14502781
[TBL] [Abstract][Full Text] [Related]
14. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
15. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Vazquez-Martin A; Colomer R; Menendez JA
Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
[TBL] [Abstract][Full Text] [Related]
16. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
Ray A; Naik SL; Sharma BK
Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
18. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
[TBL] [Abstract][Full Text] [Related]
19. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
20. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests.
Bánkfalvi A; Boecker W; Reiner A
Int J Oncol; 2004 Oct; 25(4):929-35. PubMed ID: 15375542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
